CD117在急性白血病中的表达及临床意义

目的探讨CD117在急性白血病中的表达及其临床意义。方法应用CD45/SSC设门,直接荧光标记法,经流式细胞术对73例急性髓系白血病（AML）和47例急性淋巴细胞白血病（ALL）进行CD117的检测。结果对照组、ALL及AML3组CD117的表达阳性率差异有统计学意义（χ2=41.681,P﹤0.01）。AML组CD117的表达阳性率（58.9%）明显高于对照组（0）及ALL组（8.5%）。CD117/CD34的共表达率ALL组明显低于AML组（4.3%vs45.2%,P﹤0.05）。AML组CD117＋患者的CR率为60.5%,CD117-患者为76.7%,两者比较差异无统计学意义（P〉0.05）;而CD117＋/CD34＋患者的CR率为54.5%,明显低于CD117-/CD34-患者的CR率（88.2%,P﹤0.05）。结论 CD117可作为辅助诊断AML的髓系标志抗原,CD34＋/CD117＋可作为进一步排除ALL的指标。CD117＋/CD34＋可能是AML中一类预后不良的特殊亚型,可以作为AML预后判断的指标之一。     

同系大鼠骨髓间充质干细胞对同种异体胰岛刺激的T淋巴细胞的免疫调节作用

目的:研究同系大鼠骨髓间充质干细胞(Mesenchymal stem cell,MSC)对同种异体胰岛刺激的T淋巴细胞的免疫调节作用,以及对共培养胰岛胰岛素分泌的影响。方法:以Wistar大鼠胰岛作为刺激原,Lewis大鼠MSC及外周血T淋巴细胞作为共培养细胞,分为三组:实验组(A)20IEQ胰岛细胞、1×108 L-1 T淋巴细胞和1×107 L-1 MSCs共培养;药物对照组(B)20IEQ胰岛细胞与1×108 L-1 T淋巴细胞共培养并加入0.25μg/ml CsA;阳性对照组(C)20IEQ胰岛细胞与1×108 L-1 T淋巴细胞共培养。CCK-8检测共培养3天时T淋巴细胞对同种异体胰岛刺激的反应性,ELISA检测共培养3天时上清液IFN-γ、IL-2、IL-4和IL-10的含量,以及共培养胰岛的胰岛素分泌功能。结果:MSC与CsA均可抑制同种异体胰岛刺激的T淋巴细胞增殖,A组T淋巴细胞增殖率(17.10±2.7)%与B组(14.65±1.8)%间差异无统计学意义(P>0.05);C组IFN-γ、IL-2含量显著高于A组及B组,IL-10含量显著低于A及B组,差异有统计学意义(P<0.05);IL-4含量在A、B、C三组间差异均无统计学意义(P>0.05)。A组胰岛的胰岛素分泌水平显著高于B组和C组,差异有统计学意义(P<0.05);胰岛素刺激指数(2.37±0.52)显著高于B组(1.80±0.36),差异有统计学意义(P<0.05)。结论:MSC与CsA均可通过减少Th1类细胞因子的表达使受者Th1/Th2平衡向Th2方向偏移,抑制同种异体胰岛刺激的T淋巴细胞增殖。相对于CsA,MSC可以保持胰岛素高分泌水平和良好的糖刺激反应性,避免了CsA可能带来的毒性和副作用,具有一定的临床应用优势及前景。     

circ_0079593对儿童急性淋巴细胞白血病KOCL44细胞增殖和凋亡的影响及分子机制研究

目的 探讨circ_0079593对儿童急性淋巴细胞白血病(ALL)KOCL44细胞增殖和凋亡的影响及分子机制.方法 收集27例急性淋巴细胞白血病患儿和健康志愿者的外周血,RT-qPCR检测circ_0079593和miR-1299的表达水平;将 KOCL44细胞随机分为 si-NC 组、si-circ_0079593...     

F11 rs2289252基因多态性与急性白血病患者出血相关性分析

目的:探讨凝血因子Ⅺ(F11)rs2289252 C/T基因多态性与急性白血病(AL)患者临床出血的关系。方法:2016-09—2018-09在荆州市中心医院诊治的90例AL患者[急性髓细胞白血病(AML)70例、急性淋巴细胞白血病(ALL组)20例]和104例体检健康者(正常对照组)。根据入院时患者有无出血将各组AL患者分为未出血组与出血组两个亚组。采用Sanger测序法对所有受试者rs2289252进行单核苷酸多态性(SNP)检测。分析各组rs2289252基因型频率、等位基因频率的差异及其与AL患者出血的关系。结果:各组rs2289252基因型分布差异无统计学意义(P0.05),各组rs2289252等位基因频率差异有统计学意义(P0.05)。AML患者出血组rs2289252多态性位点的T等位基因频率显著低于未出血组。ALL患者未出血组与出血组各基因型频率及等位基因频率差异无统计学意义(P0.05)。AML患者中,rs2289252 TC携带者出血风险是CC的0.256倍(95%CI:0.081-0.808,P0.05)。结论:F11 rs2289252基因多态性与AML出血相关,T等位基因可能是AML出血的保护因素。     

南方汉族KIR-HLA系统分子遗传多态性与急性白血病的相关性

目的:探讨中国南方汉族人群KIR-HLA系统分子遗传多态性与急性淋巴细胞白血病(acute lymphoblastic leukemia, ALL)、急性髓系白血病(acute myelocytic leukemia, AML)的相关性。方法:对323份成年ALL、350份成年AML患者以及745份随机健康对照的样本,...     

乳腺癌异常表达B7-H4对T细胞分泌细胞因子和凋亡的影响 乳腺癌异常表达B7-H4对T细胞分泌细胞因子和凋亡的影响

目的：探讨B7-H4在乳腺癌中的表达及其对外周血T细胞分泌细胞因子及增殖、凋亡的影响。方法：应用S-P免疫组化法检测B7-H4在乳腺浸润性癌、癌旁组织和纤维腺瘤的表达。流式细胞术分析B7-H4对乳腺癌患者外周血活化T细胞增殖和凋亡的作用。ELISA芯片检测T细胞培养上清液细胞因子的含量。结果：B7-H4在乳腺浸润性癌的阳性表达率为84.62%(44/52),显著高于癌旁组织和纤维腺瘤组织（P<0.01,P<0.01 ）。体外淋巴细胞混合培养结果显示,与空白组比较,B7-H4对乳腺癌患者外周血活化T细胞的增殖指数Ki67无明显影响;但B7-H4诱导CD8+T细胞凋亡的作用强于CD4+T 细胞。B7-H4组FOXP3+T/CD4+T也高于空白组（P<0.05 ）。B7-H4组较空白组细胞培养上清液中TGF-β1、IL-17含量均显著增高（P<0.05,P<0.05）。结论：乳腺浸润性癌异常表达B7-H4。B7-H4在体外能促进CD8+T细胞凋亡、促进T细胞分泌TGF-β1 和IL-17。B7-H4在削弱乳腺癌微环境的抗肿瘤细胞免疫中发挥一定作用。     

HLA-DRB1基因多态性与急性淋巴细胞白血病和慢性髓性白血病易感性关联的研究

目的探讨急性淋巴细胞白血病（ALL）和慢性髓性白血病（CML）易感性与HLA-DRB1基因多态性之间的关联性,找出急性淋巴细胞白血病和慢性髓性白血病的易感基因。方法采用序列特异性引物聚合酶链反应（PCR-SSP）DNA分型技术对56例ALL患者、48例CML患者和105例健康对照进行了HLA-DRB1基因分型。结果ALL患者组与HLA-DR7基因关联,基因频率为24.1%,RR=2.56,χ     

伴11q23异常的急性髓系白血病的细胞遗传学分析

11q23易位在急性白血病（acute leukemia，AL）中是常发生的遗传学改变，表现异常的临床和生物学特征，可见于急性髓细胞白血病（acute myeloid leukemia，AML）、急性淋巴细胞白血病（acute lymphoblastic leukemia，ALL）、骨髓增生异常综合征（myelodysplastic syndrome，MDS）、Ph染色体阴性的慢性粒细胞白血病和治疗相关性白血病等多种恶性血液病。     

干扰素-α联合GM－CSF诱导慢性髓性白血病细胞向树突状细胞分化

目的：研究干扰素-α（IFN-α）对慢性髓性白血病（CML）骨髓单个核细胞来源的树突状细胞（DCs）发育的影响。 方法： 12例初发慢性期CML患者的骨髓单个核细胞，分别与含如下细胞因子,RPMI-1640培养液共育：rhGM-CSF 1×106U/L联合rhIFN-α 2×106U/L（IFN-α组）、rhGM-CSF 1×10⁶U/L联合rhIL-4 5×10⁵U/L（IL-4组）、单用rhGM-CSF 1×10⁶U/L和单用rhIFN-α 2×106U/L，培养7 d；于第8-10 d，部分孔加入rhTNF-α 5×10⁴U/L。形态学（Wright染色、倒置显微镜）、免疫学（CD80、CD86、CD83、CD1a、HLA-DR）检测；磷脂酰丝氨酸（PS）转位检测 DCs凋亡情况；荧光原位杂交（FISH）对1例CML进行细胞遗传学分析；混合淋巴细胞反应（MLR）检测刺激同种异体T淋巴细胞增殖的能力。 结果： CML骨髓单个核细胞经上述细胞因子诱导7 d后，IFN-α组和IL-4组均呈现树突状细胞的典型形态；免疫学鉴定，IFN-α组DCs CD80、CD86、CD83、HLA-DR的表达显著高于IL-4组（P<0.05），经5×104U/L rhTNF-α作用后，两组DCs CD80、CD86、CD83、HLA-DR进一步上调，其中IFN-α组DCs CD80、CD86、CD83、HLA-DR的表达显著高于IL-4组（P<0.05）；经FISH证实来源于白血病细胞；两组DCs均具有刺激同种异体T淋巴细胞增殖的能力，IFN-α组刺激淋巴细胞增殖的能力明显高于IL-4组(P<0.05)。 结论： IFN-α可促进CML骨髓单个核细胞来源的树突状细胞的分化、活化。这可能是IFN-α在CML中的治疗机制之一。     

间充质干细胞对系统性红斑狼疮T淋巴细胞的免疫调节作用

目的研究正常健康捐献者骨髓来源的间充质干细胞(MSC)对系统性红斑狼疮(SLE)患者来源的T淋巴细胞的免疫调节作用。方法共培养MSC与正常对照或SLE患者来源的T淋巴细胞,检测MSC对T细胞的作用,包含T细胞增殖能力,细胞表型及其产生的细胞因子等。实验分为健康对照组(C组)与SLE组(S组)。每一大组又分为T细胞组(C1组、S1组)、T细胞+植物血凝素组(C2组、S2组)、T细胞+植物血凝素+MSC组(C3组、S3组)。结果 MSC能抑制SLE患者来源的T淋巴细胞增殖[S2:(2 615.7±582.3)cpm;S3:(784.7±417.5)cpm;P0.05],促使SLE T细胞向调节性CD4+CD25+Foxp3+T细胞转化增加(S2:11.85%±1.99%;S3:24.17%±5.82%,P0.05)。MSC还能促使SLE T细胞分泌IFN-γ[S2:(14.13±11.16)pg/ml;S3:(39.68±26.73)pg/ml,P0.05]与IL-10[S2:(5.09±2.96)pg/ml;S3:(17.15±3.61)pg/ml,P0.05]。结论 MSC能抑制SLE患者来源的T细胞增殖,促进T细胞向调节性T细胞转化,诱导免疫耐受,有望成为治疗SLE的细胞疗法。     

Extramedullary Relapse of Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Different Characteristics between Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia

Extramedullary relapse (EMR) of acute leukemia (AL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a contributor to post-transplantation mortality and remains poorly understood, especially the different characteristics of EMR in patients with acute myelogenous leukemia (AML) and those with acute lymphoblastic leukemia (ALL). To investigate the incidence, risk factors, and clinical outcomes of EMR for AML and ALL, we performed a retrospective analysis of 362 patients with AL who underwent allo-HSCT at the First affiliated Hospital of Soochow University between January 2001 and March 2012. Compared with patients with AML, those with ALL had a higher incidence of EMR (12.9% versus 4.6%; P = .009). The most common site of EMR was the central nervous system, especially in the ALL group. Multivariate analyses identified the leading risk factors for EMR in the patients with AML as advanced disease status at HSCT, hyperleukocytosis at diagnosis, history of extramedullary leukemia before HSCT, and a total body irradiation–based conditioning regimen, and the top risk factors for EMR in the patients with ALL as hyperleukocytosis at diagnosis, adverse cytogenetics, and transfusion of peripheral blood stem cells. The prognosis for EMR of AL is poor, and treatment options are very limited; however, the estimated 3-year overall survival (OS) was significantly lower in patients with AML compared with those with ALL (0 versus 18.5%; P = .000). The characteristics of post–allo-HSCT EMR differed between the patients with AML and those with ALL, possibly suggesting different pathogenetic mechanisms for EMR of AML and EMR of ALL after allo-HSCT; further investigation is needed.     

Defects of natural killer cell activity in children with untreated acute lymphocytic leukemia

Summary Natural killer (NK) activity against cells of the K-562 line was significantly depressed in 12 of 18 children (66%) with untreated acute lymphocytic leukemia (ALL). No suppression of allogeneic NK activity was observed with sera of the patients, regardless of the level of NK depression. The ability of peripheral blood lymphocytes (PBLs) to suppress allogeneic NK activity was tested in two ALL patients — one with no detectable NK activity, and one with high NK activity. No NK-suppressive activity was found with PBLs of the areactive patient; PBLs of the reactive patients exhibited some suppressive activity, but only at a particular suppressor-to-effector cell ratio. Leukemic blasts were resistant to killing by autologous NK cells stimulated by IFN, as well as to killing by allogeneic, IFN-stimulated PBLs. Leukemic blasts of an ALL patient inhibited lysis of K-562 cells in an 18-h, but not in a 4-h NK assay. The inhibition could partly be reversed by pretreatment of ALL cells with alpha interferon, suggesting that the blasts might inhibit the lysis of K-562 targets in a competitive manner. Disturbed function and/or regulation of NK cells may influence attempts at NK cell activation by lymphokines.Abbreviations ALL acute lymphocytic leukemia - AML acute myeloid leukemia - CLL chronic lymphocytic leukemia - CML chronic myeloid leukemia - IFN interferon - IL-2 interleukin-2 - LGL large granular lymphocyte - NK cell natural killer cell - PBL peripheral blood lymphocyte - Poly I:C polyinosinic-polycytidylic acid     

初发急性髓性白血病患者外周血中高表达TAL1基因及其意义

目的:分析调控造血分化的重要转录因子TAL1在急性髓性白血病(AML)细胞株及原代AML细胞中的表达特点。方法:利用real-time PCR法分别检测47例初发急性髓性白血病患者外周血单个核细胞以及急性白血病细胞株(Jurkat、CCRF-CEM、HL-60和NB4细胞株)中TAL1 mRNA的水平,并以12例健康志愿者外周血样本作为对照组。结果:TAL1 mRNA在AML细胞株(HL-60和NB4)、T细胞急性淋巴细胞白血病(T-ALL)细胞株(Jurkat和CCRF-CEM)和原代AML细胞中的水平均显著高于健康对照组(P0.05)。各AML亚型中TAL1的mRNA表达水平均较对照组显著升高,并以AML-M1和AML-M5 2个亚型升高最为明显(P0.05)。结论:AML细胞中TAL1异常高表达可能与其影响粒系的分化发育有关,其能否作为AML发病相关分子标志物有待进一步研究。     

Loss or downregulation of HLA class I expression at the allelic level in acute leukemia is infrequent but functionally relevant, and can be restored by interferon

Human leukocyte antigen (HLA) class I expression at the allelic level was analyzed in 397 acute myeloid leukemia (AML) and 186 acute lymphoid leukemia (ALL) using a complement-dependent cytotoxicity assay. Impaired recognition possibly due to HLA downregulation was observed in 2% of the patients with AML and ALL in complete remission, and in 8%-15% in the groups with blasts. In 15 instances of diminished cytotoxicity, leukemic cells and control PHA blasts from the same patients were further analyzed using flow cytometry. In 4/6 ALL and 4/9 AML patients HLA downregulation or complete loss (2 patients) of cell surface expression could be confirmed. No genomic abnormalities were observed. In addition, 12 AML and 13 ALL patients were tested during relapse using flow cytometry. In 1/12 AML patients and 1/13 ALL patients allelic downregulation of cell surface expression was found. In two patients tested, downregulation or loss of cell surface expression of HLA class I antigens corresponded with impaired T cell mediated lysis by HLA restricted cytotoxic T lymphocyte.Treatment of the cells with alpha- or gamma-interferon could restore HLA class I expression and T-cell recognition. In conclusion, downregulation of cell surface expression of HLA class I expression at the allelic level in AML and ALL is infrequent but functionally relevant. HLA downregulation was reversible and T-cell recognition could be restored by alpha- or gamma-interferon.     

Distinct Clinical Features of Infectious Complications in Adult T Cell Leukemia/Lymphoma Patients after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis in the Nagasaki Transplant Group

Although allogeneic hematopoietic stem cell transplantation (allo-SCT) is performed as a curative option in adult T cell leukemia-lymphoma (ATL) patients, its high transplantation-related mortality raises a serious issue. The clinical features of infectious complications after transplantation are not well known. To analyze the impact of infections after allo-SCT for ATL, we retrospectively compared infectious complications in 210 patients at 3 institutions in Nagasaki prefecture between 1997 and 2009. There were 91 patients with acute myeloid leukemia (AML), 51 with acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL), and 68 with ATL. No patient received ganciclovir or foscarvir as prophylaxis, and most patients received antifungal prophylaxis with fluconazole or itraconazole. The cumulative incidence of cytomegalovirus (CMV) infection at 3 years was 69.2% in ATL patients versus 54.4% in AML patients (P = .0255). Cumulative infection-related mortality was significantly higher in ATL patients than in the 2 other groups (ATL versus AML, P = .0496; ATL versus ALL/LBL, P = .0075), and most death-causing pathogens were bacteria and fungus. The appearance of CMV infection was negatively associated with infectious mortality in ATL patients, but the P value for this association was near the borderline of significance (P = .0569). In multivariate analysis, transplantation using unrelated bone marrow and episodes of CMV infection were associated with worse overall survival in ATL patients, but were not in either AML or ALL/LBL patients. Collectively, the impact of infectious complications after transplantation in ATL patients was different from that in AML and ALL/LBL patients, suggesting that a more intensive strategy for infection control in ATL patients is required to reduce infectious mortality.     

Implication of Early Lymphocyte Recovery after Allogeneic Hematopoietic Stem Cell Transplantation in Children with Leukemia

Purpose

The repopulating lymphocytes after allogeneic hematopoietic stem cell transplantation have an important role not only on the prevention of serious infections in the early transplantation period, but also on the killing of residual leukemic cells by graft-versus-leukemia effect. The aim of this study was to analyze the impact of lymphocyte recovery after allogeneic stem cell transplantation in children with hematologic malignancies.

Materials and Methods

We evaluated 69 children transplanted for acute lymphoblastic leukemia (ALL) (n=34), acute myeloid leukemia (AML) (n=26), chronic leukemia (n=7) and juvenile myelomonocytic leukemia (n=2) between 1996 and 2008 at the Chonnam National University Hospital, Korea. The patients were grouped based on absolute lymphocyte counts (ALC) <500/µL or ≥500/µL at D+21 and D+30 after transplant.

Results

Patients with a High ALC at D+21 and D+30 had a faster neutrophil and platelet engraftment. The High at D+30 group had a better 5 year overall survival (71% vs. 53%, p=0.043) and event-free survival (72% vs. 53%, p=0.065) than the Low at D+30 group. The incidence of grade II-IV acute and chronic graft-versus-host disease (GVHD), and relapse rate did not differ by the ALC counts. However, the Low at D+30 group had a significantly increased risk for transplant-related mortality (p=0.019). The univariate analysis showed that the factors associated with decreased survival were a Low ALC at D+30, patients with high risk ALL, and grade II-IV aGVHD in patients with ALL and AML.

Conclusion

Early posttransplant serial lymphocyte measurement would be a simple but useful method for predicting transplant outcomes.     

Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia

The quantitative levels of intracellular cytokines IL-4, IL-10, and IFN-gamma (ie, the number of bound PE-conjugated antibody molecules/cell) of leukemic cells and bone marrow T cells (bmT cells) of acute leukemia patients were analyzed by flow cytometry. One hundred, thirty-one (95 AML, 25 ALL, 11 ABL) patients were studied. The leukemic cell IL-4 level was highest in the monocytic AML group (1735 +/- 1056) and lowest in the dysplastic AML group (960 +/- 545). The IFN-gamma level was highest in the acute promyelocytic leukemia (APL) group (495 +/- 159), and lowest in the ALL group (252 +/- 119). The IL-10 level was not significantly different among the diagnosis groups. In bmT cells, the IL-10 level was highest in the dysplastic AML group (972 +/- 1049) and lowest in the APL group (397 +/- 352). The leukemic cell cytokine levels were lowest and bmT cell cytokine levels were highest in the dysplastic AML group. There were no significant correlations of these cytokine levels with 2-yr survival rate, complete remission (CR) rate, or relapse rate. The cytokine levels of bmT cells at the time of CR became normal and were not different among the diagnosis groups. In summary, leukemic cell and bmT cell cytoplasmic expression profiles of IL-4, IL-10, and IFN-gamma are characteristic for each diagnostic group of acute leukemia patients and the profiles of bmT cells are normal at the time of CR.     

Second Hematopoietic Stem Cell Transplantation for Post-Transplantation Relapsed Acute Leukemia in Children: A Retrospective EBMT-PDWP Study

Outcome data were collected from the European Society for Blood and Marrow Transplantation registry on 373 children from 120 centers with relapsed leukemia (214 with acute lymphoblastic leukemia [ALL] and 159 with acute myelogenous leukemia [AML]) who underwent second allogeneic hematopoietic stem cell transplantation (HSCT) between 2004 and 2013. Overall survival (OS) was 38% at 2 years and 29% at 5 years, and leukemia-free survival (LFS) was 30% at 2 years and 25% at 5 years. Median follow-up after second HSCT was 36.4 months in the ALL group and 50.2 months in the AML group. In the ALL group, OS was 43% at 2 years and 33% at 5 years, and LFS was 34% at 2 years and 31% at 5 years. In the AML group, OS was 32% at 2 years and 24% at 5 years, and LFS was 24% at 2 years and 17% at 5 years. The 2-year nonrelapse mortality (NRM) rate was 22% in the ALL group and 18% in the AML group. Favorable prognostic factors (P?<?.05) for OS and LFS included >12 months between transplantations and chronic graft-versus-host disease after the first HSCT (in both groups), complete response before the second HSCT (ALL group only), and age >12 years (AML group only). Findings were more consistent over time in the ALL group, with no significant differences between 2-year and 5-year rates of relapse, NRM, and LFS. Children with relapsed acute leukemias have a substantial likelihood of long-term survival following second HSCT. Given the many novel targeted and immunomodulation therapies currently under development, it is important to identify specific patient subpopulations that may benefit from a second HSCT compared with those better suited to new approaches.     

急性髓系白血病患者治疗前后T淋巴细胞亚群测定的临床意义

为探讨急性髓系白血病患者治疗前后T淋巴细胞亚群变化的临床意义,选择初发确诊的急性髓系白血病患者30例(初治组); 经标准方案化疗,26例完全缓解(缓解组); 健康人30名(正常对照组).应用流式细胞术检测这三组人群T淋巴细胞亚群的变化情况.结果显示,初治组CD3+T 细胞、CD4+T细胞、CD8+T细胞百分率、CD4+...     

亚硒酸钠对慢性乙型肝炎病毒感染者外周血树突状细胞功能的影响

目的 探讨体外培养诱导慢性乙型肝炎患者外周血树突状细胞(DCs)功能状态改善的方法.方法 用GM-CSF IL-4 INF-a诱生慢性乙型肝炎患者及健康人外周血来源的DCs,在乙肝患者DCs成熟前加入营养浓度的硒(0.3mmol/L)共培养.流式细胞仪(FCM)检测细胞表面CD80、CD86表达水平,四甲基偶氮唑盐比色法(MTT法)检测DCs刺激同种异体淋巴细胞增殖能力及酶联免疫吸附测定法(ELISA法)检测DCs培养上清中白细胞介素12(IL-12)的分泌水平.结果 经营养浓度硒(0.3mmol/L)作用后的乙肝患者的DCs刺激淋巴细胞增殖能力明显高于未经硒作用的乙肝组(P<0.01),IL-12的分泌水平和表面刺激分子也明显高于乙肝组(P<0.01),加硒组和健康组之间则没有显著性差异.结论 体外经营养浓度的硒作用后的乙肝患者的DCs可有效刺激淋巴细胞增殖反应,提高IL-12分泌水平,在一定程度上能恢复DCs的免疫功能,这些为今后DCs的慢性乙型肝炎的免疫治疗提供新思路.